The in vivo results had shown that the bispecific LAG-3xPD-L1 antibody reprogrammed the tumor microenvironment by enhancing dendritic cell activation, promoting antigen cross-presentation, and inducing stronger CD8+ T cell activation compared to a combination of anti-LAG-3 and anti-PD-L1 antibodies. This evidence concerns the gene CD8A and neoplasm.